ONCOLOGÍA MÉDICA

2011

Artículos

Castellano D. Gastroenteropancreatic neuroendocrine tumors. Where are we now? Cancer Metastasis Rev. 2011;30(Suppl 1):1.

Castellano D, González Larriba JL, Antón Aparicio LM, Cassinello J, Grande E, Esteban E, et al. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients. Expert Opin Pharmacother. 2011;12(16):2433-9.

Castellano D, Salazar R, Raymond E. Future perspectives on neuroendocrine tumors. Cancer Metastasis Rev. 2011;30(Suppl 1):35-40.

Castellano D, Sepúlveda JM, García Escobar I, Rodriguez Antolín A, Sundlöv A, Cortés-Funes H. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist. 2011;16(2):136-45.

Cortés-Funes H, Ghanem I. Safety and efficacy of moderate-dose capecitabine as first-line therapy in metastatic breast cancer. Expert Rev Anticancer Ther. 2011;11(2):165-8.

García Escobar I, Sepúlveda J, Castellano D, Cortés-Funes H. Therapeutic management of chronic lymphocytic leukaemia: state of the art and future perspectives. Crit Rev Oncol Hematol. 2011;80(1):100-13.

Gómez Martín C, Hidalgo M, Tabernero J, Isla D. SEOM clinical guidelines for the treatment of pancreatic cancer. Clin Transl Oncol. 2011;13(8):528-35.

Grávalos C, García Alfonso P, Afonso R, Arrazubi V, Arrivi A, Cámara JC, et al. Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain. Clin Transl Oncol. 2011;13(12):862-8.

Grávalos C, Gómez Martín C, Rivera F, Alés I, Queralt B, Márquez A, et al. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol. 2011;13(3):179-84.

Medina Polo J, Martínez Silva V, Domínguez Esteban M, De la Rosa Kehrmann F, Villacampa Aubá F, Castellano Gauna D, et al. Testicular tumors: residual retroperitoneal mass surgery after chemotherapy; Is it  possible to predict their histology? Arch Esp Urol. 2011;64(7):611-9.

.

2012

Artículos

Castellano D, Carles J, Esteban E, Trigo JM, Climent MA, Maroto JP, et al. Recommendations for the optimal management of early and advanced urothelial carcinoma. Cancer Treat Rev. 2012;38(5):431-41.

Castellano D, Virizuela JA, Cruz J, Sepúlveda JM, Sáez MI, Sáenz M, et al. The role of pharmacogenomics in metastatic renal cell carcinoma. Cancer Metastasis Rev. 2012;31 Suppl 1:S29-32. Erratum in: Cancer Metastasis Rev. 2013;32(1-2):317.

Grávalos C, Salut A, García Girón C, García Carbonero R, León AI, Sevilla I, et al. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. Clin Transl Oncol. 2012;14(8):606-12.

Grávalos C, Salvador J, Albanell J, Barnadas A, Borrega P, García Mata J, et al. Functions and workload of medical oncologists in Spain. Clin Transl Oncol. 2012;14(6):423-9.

Gómez Martín C, Sánchez A, Irigoyen A, Llorente B, Pérez B, Serrano R, et al. Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. Clin Transl Oncol. 2012;14(9):689-97.

Hilario A, Ramos A, Pérez Núñez A, Salvador E, Millán JM, Lagares A, et al. The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas. AJNR Am J Neuroradiol. 2012;33(4):701-7.

Hitt R, Irigoyen A, Cortés-Funes H, Grau JJ, García Sáenz JA, Cruz Hernandez JJ, et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23(4):1016-22.

Paz-Ares L, López Pousa A, Poveda A, Balañá C, Ciruelos E, Bellmunt J, et al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs. 2012;30(2):729-40.

.

2013

Artículos

Alba E, Ciruelos E, López R, López Vega JM, Lluch A, Martín M, et al. Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain. Expert Rev Pharmacoecon Outcomes Res. 2013;13(3):381-91 [PubMed]

Angevin E, López Martín JA, Lin CC, Gschwend JE, Harzstark A, Castellano D, et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res. 2013;19(5):1257-68 [PubMed]

Awada A, Dirix L, Manso Sánchez L, Xu B, Luu T, Diéras V et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. 2013
Jan;24(1):109-16 [PubMed]

Caraceni A, Davies A, Poulain P, Cortés Funes H, Panchal SJ, Fanelli G. Guidelines for the management of breakthrough pain in patients with cancer. J Natl Compr Cancer Netw. 2013;11:S29-36 [PubMed]

Carrato A, Gómez A, Escudero P, Chaves M, Rivera F, Marcuello E, et al. Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. Clin Transl Oncol. 2013;15(9):705-11 [PubMed]

Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O’Dorisio T, et al. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study. Oncologist. 2013;18(1):46-53 [PubMed]

Castellano D, Capdevila J, Sastre J, Alonso V, Llanos M, García Carbonero R, et al. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). Eur J Cancer. 2013;49(18):3780-7 [PubMed]

Castellano D, Duh MS, Korves C, Suthoff ED, Neary M, Hernández Pastor LJ, et al. Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain. Expert Opin Drug Saf. 2013;12(4):455-63 [PubMed]

Castellano D, Ravaud A, Schmidinger M, De Velasco G, Vázquez F. Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers. Cancer Treat Rev. 2013;39(3):230-40 [PubMed]

Castellano D, Virizuela JA, Cruz J, Sepúlveda JM, Sáez MI, Paz Ares L. Erratum to: The role of pharmacogenomics in metastatic renal cell carcinoma. Cancer Metastasis Rev. 2013;32(1-2):317 [PubMed]

Ciruelos E, Cortés Funes H, Ghanem I, Manso L, Arteaga C. Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer. Anticancer Drugs. 2013;24(8):769-80 [PubMed]

Cortijo Cascajares S, Nacle López I, García Escobar I, Aguilella Vizcaíno MJ, Herreros de Tejada A, Cortés Funes Castro H, et al. Effectiveness of oxaliplatin desensitization protocols. Clin Transl Oncol. 2013;15(3):219-25 [PubMed]

De Dosso S, Grande E, Barriuso J, Castellano D, Tabernero J, Capdevila J. The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation. Cancer Metastasis Rev. 2013 Dec;32(3-4):465-77. [PubMed]

Del Barco S, Ciruelos E, Tusquets I, Ruiz M, Barnadas A. SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013. Clin Transl Oncol. 2013;15(12):1011-7 [PubMed]

Díaz García CV, Agudo López A, Pérez C, López Martín JA, Rodríguez Peralto JL, De Castro J, et al. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification. Carcinogenesis. 2013;34(5):1031-8 [PubMed]

Finn RS, Poon RTP, Yau T, Klümpen HJ, Chen LT, Kang YK, et al. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. J Hepatol. 2013;59(6):1271-7 [PubMed]

Gámez Pozo A, Ferrer NI, Ciruelos E, López Vacas R, Martínez FG, Espinosa E, et al. Shotgun proteomics of archival triple-negative breast cancer samples. Proteomics Clin Appl. 2013;7(3-4):283-91 [PubMed]

García Donas J, Leandro García LJ, González del Alba A, Morente M, Alemany I, Esteban E, et al. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol. 2013;24(9):2409-14 [PubMed]

Garon EB, Reck M, Paz Ares L, Ponce S, Jaime JC, Juan O, et al. Treatment rationale and study design for the RELAY study: A multicenter, randomized, double-blind study of erlotinib with ramucirumab or placebo in patients with epidermal growth factor receptor mutation-positive metastatic non-small-cell lung cancer. Clin Lung Cancer. 8 de junio de 2016 [PubMed]

Gascón P, Rodríguez CA, Valentín V, Mata JG, Carulla J, Cassinello J, et al. Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: a prospective, observational study. Support Care Cancer. 2013;21(11):3039-49 [PubMed]

Gómez Martín C, Salazar R, Montagut C, Gil Martín M, Núñez JA, Puig M, et al. A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. Invest New Drugs. 2013;31(2):390-8 [PubMed]

González Martín A, Redondo A, Jurado M, De Juan A, Romero I, Bover I, et al. GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clin Transl Oncol. 2013;15(7):509-25 [PubMed]

Grávalos C, Rodríguez C, Sabino A, Seguí MÁ, Virizuela JA, Carmona A, et al. SEOM Clinical Guideline for bone metastases from solid tumours (2016). Clin Transl Oncol. 28 de noviembre de 2016 [PubMed]

Hochhauser D, Glynne Jones R, Potter V, Grávalos C, Doyle TJ, Pathiraja K, et al. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther. 2013;12(5):809-18 [PubMed]

Kamieniak MM, Muñoz Repeto I, Rico D, Osorio A, Urioste M, García Donas J, et al. DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas. Br J Cancer. 2013;108(8):1732-42 [PubMed]

Lastra Aras E, Robles Díaz L, Guillén Ponce C, Alba E, Cruz J-J. SEOM recommendations on the structure and operation of hereditary cancer genetic counseling units (HCGCUs). Clin Transl Oncol. 2013;15(1):20-5 [PubMed]

Liu X, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RHJ, et al. Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. Oncotarget. 25 de noviembre de 2016 [PubMed]

Manso L, Valdiviezo N, Sepúlveda J, Ciruelos E, Mendiola C, Ghanem I, et al. Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients. Clin Transl Oncol. 2013;15(6):467-71 [PubMed]

Martín M, Ruiz A, Ruiz Borrego M, Barnadas A, González S, Calvo L, et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. J Clin Oncol. 2013 Jul 10;31(20):2593-9. [PubMed]

Martín Pérez E, Capdevila J, Castellano D, Jiménez Fonseca P, Salazar R, Beguiristain Gómez A, et al. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE). Neuroendocrinology. 2013;98(2):156-68 [PubMed]

Martin Richard M, Díaz Beveridge R, Arrazubi V, Alsina M, Galan Guzmán M, Custodio AB, et al. SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016). Clin Transl Oncol. 29 de noviembre de 2016[PubMed]

Martin Richard M, Massutí B, Pineda E, Alonso V, Mármol M, Castellano D, et al. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. BMC Cancer. 2013;13:427 [PubMed]

Maurel J, Grávalos C, Rivera F, Vera R, González Flores E. SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013. Clin Transl Oncol. 2013;15(12):991-5 [PubMed]

Meneses JC, Ávila Martínez RJ, Ponce S, Zuluaga M, Bartolomé A, Gámez P. Tratamiento del carcinoma broncogénico de célula no pequeña en estadios precoces. Cir Esp.  2013;91(10):625-32 [PubMed]

Metola Gómez A, García Romo E, Bellido de Vega S, Carretero Lanchas Y, Azcoitia Álvarez B, Guerrero L. Análisis de la evolución de pacientes en probable situación de últimos días en un servicio de Urgencias. Med. Paliat. 2013; 20(1):10-8.

Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055-66 [PubMed]

Moreno Aspitia A, Dueck AC, Ghanem Canete I, Patel T, Dakhil S, Johnson D, et al. RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Res Treat. 2013;138(2):427-35 [PubMed]

Muñoz Repeto I, García MJ, Kamieniak M, Ramón y Cajal T, Domingo S, Cazorla A, et al. Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study. Histol Histopathol. 2013;28(1):133-44 [PubMed]

Pozo N, Zahonero C, Fernández P, Liñares JM, Ayuso A, Hagiwara M, et al. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth. J Clin Invest. 2013;123(6):2475-87 [PubMed]

Ramos A, Hilario A, Lagares A, Salvador E, Pérez Núñez A, Sepúlveda J. Brainstem gliomas. Semin Ultrasound CT MR. 2013;34(2):104-12 [PubMed]

Salazar R, Cortés Funes H, Casado E, Pardo B, López Martín A, Cuadra C, et al. Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;72(1):75-83 [PubMed]

Sangro B, Gómez Martín C, De la Mata M, Iñarrairaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81-8 [PubMed]

Steegmann JL, Sánchez Torres JM, Colomer R, Vaz Á, López J, Jalón I, et al. Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. Clin Transl Oncol. 2013;15(6):477-83 [PubMed]

Sternberg CN, Skoneczna IA, Castellano D, Theodore C, Blais N, Voog E, et al. Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB). Oncology. 2013;85(4):208-15 [PubMed]

Swain SM, Kim S-B, Cortes J, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461-71 [PubMed]

Congresos

Aparicio LA, Sánchez Hernández A, Esteban E, Germa JR, Batista N, Maroto P, et al. Cabazitaxel for metastatic castration-resistant prostate cancer: Safety data from the Spanish Early Access Programme. Eur J Cancer. 2013;49:S694 [European Cancer Congress (17. Amsterdam, Netherlands. 2013)]

Capdevila J, Castellano DE, García Carbonero R, Teule A, Duran I, Fuster J, et al. «Pazonet»: Single-arm multicentric phase II trial of pazopanib in patients with progressive gastroenteropancreatic neuroendocrine tumors (GEPNETs). Eur J Cancer. 2013;49:S615-6 [European Cancer Congress (17. Amsterdam, Netherlands. 2013)]

Casanovas O, Figueras A, Salazar R, Castellano D, Capdevila J, García Carbonero R, et al. Plasma sVEGFR2 as predictor of efficacy of Pazopanib in patients with progressive neuroendocrine tumors: PAZONET biological Substudy. Eur J Cancer. 2013;49:S636 [European Cancer Congress (17. Amsterdam, Netherlands. 2013)]

Castellano D, Garcia del Muro X, Climent MA, Maroto P, Pérez Gracia JL, López Vivanco G, et al. Sunitinib expanded-access trial in metastatic renal cell carcinoma (mRCC) – final results from Spain. Eur J Cancer. 2013;49:S666 [European Cancer Congress (17. Amsterdam, Netherlands. 2013)]

Castellano D, Maroto P, Espinosa E, Esteban E, González de Alba A, Climent MA, et al. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: Pool analysis from 3 Spanish observational prospective studies. Eur J Cancer. 2013;49:S653-4 [European Cancer Congress (17. Amsterdam, Netherlands. 2013)]

Chirivella I, Grande E, López Criado P, González Grajera B, Fernández O, Santander C, et al. Vinflunine (VFL) as second-line chemotherapy for patients with transitional cell carcinoma of the urothelium (TCCU): A multicenter retrospective study. Eur J Cancer. septiembre de 2013;49:S671 [European Cancer Congress (17. Amsterdam, Netherlands. 2013)]

Earl J, Guerrero Arroyo C, Capdevila J, Castellano DE, García Carbonero R, Teule A, et al. Circulating tumor cells and circulating endothelial cells as predictors of efficacy of pazopanib in patients with progressive neuroendocrine tumors. Eur J Cancer. 2013;49:S577-8 [European Cancer Congress (17. Amsterdam, Netherlands. 2013)]

Escudier B, Bracarda S, Maroto JP, Szczylik C, Nathan P, Negrier S, et al. Open-label phase II trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. Eur J Cancer. 2013;49:S643 [European Cancer Congress (17. Amsterdam, Netherlands. 2013)]

García Donas J, Hernando S, Guix M, Climent M, Méndez MJ, Jiménez P, et al. Phase II study of dovitinib in first line metastatic or (non resectable primary) adrenocortical carcinoma (ACC) – SOGUG study 2011-03. Eur J Cancer. 2013;49:S659 [European Cancer Congress (17. Amsterdam, Netherlands. 2013)]

Grande E, Apellániz Ruiz M, Capdevila J, Castellano DE, García Carbonero R, Teule A, et al. Evaluation of polymorphisms as markers of pazopanib efficacy and toxicity in metastatic/advanced neuroendocrine tumors. Eur J Cancer. 2013;49:S634 [European Cancer Congress (17. Amsterdam, Netherlands. 2013)]

Méndez Vidal MJ, Laínez N, García Carbonero I, Gonzálvez ML, Castellano D, Esteban E, et al. Prospective, multicenter and epidemiological study to determine prognostic factors in patients with renal cell carcinoma: A stroma-related SNP located at FGFR2 as a potential prognostic biomarker. Eur J Cancer. 2013;49:S656 [European Cancer Congress (17. Amsterdam, Netherlands. 2013)]

Pérez Valderrama B, Villa JC, Climent MA, Lainez N, Hernando S, Font A, et al. Vinfiunine maintenance therapy vs best supportive care after platinum combination in advanced bladder cancer: A phase II, randomized, open label, study (MAJA study), SOGUG 2011-02. Eur J Cancer. 2013;49:S665 [European Cancer Congress (17. Amsterdam, Netherlands. 2013)]

Puente J, Laínez N, Castellano DE, Basterretxea L, León L, Pérez Valderrama B, et al. Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations – long term responders (LR) vs. primary refractory (PR) patients. Eur J Cancer. 2013;49:S665-6 [European Cancer Congress (17. Amsterdam, Netherlands. 2013)]

Rodríguez Garzotto A, Cortijo Cascajares S, Pernaut Sánchez C, Otero Blas I, Ruiz Ares G, Ruiz Ares G, et al. Use of erythropoiesis-stimulating agents and comparison of different products for the treatment of chemotherapy-induced anaemia (CIA). Eur J Cancer. 2013;49:S274 [European Cancer Congress (17. Amsterdam, Netherlands. 2013)]

Rubio IT, Espinosa Bravo M, Vieites B, Vilardell F, Antúnez JR, Sancho De Sala M, et al. Nomogram with total tumoral load as a novel factor to predict axillary metastasis in breast cancer. Breast. 2013;22:S54-5 [International Conference Primary Therapy of Early Breast Cancer (13. St. Gallen, Switzerland. 2013)]

Rubio E, Supelano G, García V, Butron T, Ortiz M, Cristóbal B, et al. Significance of BMI over complications in laparoscopic colorectal cancer. Eur J Cancer. 2013;49:S545 [European Cancer Congress (17. Amsterdam, Netherlands. 2013)]

Ruiz Borrego M, García Sáenz JA, Hornedo FJ, Calvo Plaza I, Lao J, Manso L, et al. First year daily clinical experience with eribulin in Spain; EUFORIA-1 study (Eribulin Use For the treatment of advanced breast cancer: Observational, Retrospective Analysis). Eur J Cancer. 2013;49:S414-5 [European Cancer Congress (17. Amsterdam, Netherlands. 2013)]

Sanz Motilva V, Martorell Calatayud A, Homet B, Vanaclocha Sebastián F, Rodríguez Peralto JL. Generalized trichilemmal cysts with an unfavorable outcome. J Am Acad Dermatol. 2013;68(4):AB161 [Annual Meeting of the American-Academy-of-Dermatology (71. Miami Beach, FL. 2013)]

Sastre J, Massuti B, Gómez A, Guillén C, Gil Calle S, Manzano JL, et al. Phase II study of first-line single-agent panitumumab in frail elderly patients with advanced wild type KRAS colorectal cancer with poor prognostic factors. Eur J Cancer. 2013;49:S552-3 [European Cancer Congress (17. Amsterdam, Netherlands. 2013)]

Stork-Sloots L, Generali D, Ciruelos E, Manso L, Ghanem I, Lifrange E, et al. European Inter-Institutional Impact Study of Mammaprint (r). Breast. 2013;22:S62-3 [International Conference Primary Therapy of Early Breast Cancer (13. St. Gallen, Switzerland. 2013)]

.

2014

Artículos

Albanell J, Ciruelos EM, Lluch A, Muñoz M, Rodríguez CA. Trastuzumab in small tumours and in elderly women. Cancer Treat Rev. 2014;40(1):41-7 [PubMed]
JCR Factor de Impacto: 7,588
JCR Cuartil: Q1
JCR Decil:D1
JCR Posición: 15/211
JCR Categoría: ONCOLOGY

Álvarez Hernández C, Vich Pérez P, Brusint B, Cuadrado Rouco C, Díaz García N, Robles Díaz L. Actualizacion del cancer de mama en Atencion Primaria (III/V). Semergen. 2014;40(8):460-72 [PubMed]
JCR Factor de Impacto: – –
JCR Cuartil: – –
JCR Decil: – –
JCR Posición: – –
JCR Categoría: – –

Andrés R, Pajares I, Balmana J, Llort G, Ramon y Cajal T, Chirivella I, et al. Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC). Clin Transl Oncol. 2014;16(3):280-4 [PubMed]
JCR Factor de Impacto: 2,077
JCR Cuartil: Q3
JCR Decil: D8
JCR Posición: 148/211
JCR Categoría: ONCOLOGY

Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem J-L, et al. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2014;20(8):2192-204 [PubMed]
JCR Factor de Impacto: 8,722
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 12/211
JCR Categoría: ONCOLOGY

Aparicio J, Maroto P, García del Muro X, Sánchez Muñoz A, Gumà J, Margelí M, et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol. 2014;25(11):2173-8 [PubMed]
JCR Factor de Impacto: 7,040
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 18/211
JCR Categoría: ONCOLOGY

Balañá C, Vaz MA, López D, De la Peñas R, García Bueno JM, Molina Garrido MJ, et al. Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain. Clin Transl Oncol. 2014;16(3):273-9 [PubMed]
JCR Factor de Impacto: 2,077
JCR Cuartil: Q3
JCR Decil: D8
JCR Posición: 148/211
JCR Categoría: ONCOLOGY

Barnadas A, Manso L, De la Piedra C, Meseguer C, Crespo C, Gómez P, et al. Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study). Bone. 2014;68:32-40 [PubMed]
JCR Factor de Impacto: 3,973
JCR Cuartil: Q2
JCR Decil: D3
JCR Posición: 38/128
JCR Categoría: ENDOCRINOLOGY & METABOLISM

Berrocal A, Arance A, López Martín JA, Soriano V, Muñoz E, Alonso L, et al. Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program. Melanoma Res. 2014;24(6):577-83 [PubMed]
JCR Factor de Impacto: 2,282
JCR Cuartil: Q2
JCR Decil: D3
JCR Posición: 16/63
JCR Categoría: DERMATOLOGY

Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;15(4):406-14 [PubMed]
JCR Factor de Impacto: 24,690
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 3/211
JCR Categoría: ONCOLOGY

Bracarda S, Castellano D, Procopio G, Sepúlveda JM, Sisani M, Verzoni E, et al. Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. Expert Opin Drug Saf. 2014;13(4):497-510 [PubMed]]
JCR Factor de Impacto: 2,911
JCR Cuartil: Q2
JCR Decil: D4
JCR Posición: 91/255
JCR Categoría: PHARMACOLOGY & PHARMACY

Castellano D, Antón Aparicio LM, Esteban E, Sánchez Hernández A, Germà JR, Batista N, et al. Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program. Expert Opin Drug Saf. 2014;13(9):1165-73 [PubMed]
JCR Factor de Impacto: 2,911
JCR Cuartil: Q2
JCR Decil: D4
JCR Posición: 91/255
JCR Categoría: PHARMACOLOGY & PHARMACY

Castellano DE, Bellmunt J, Pablo Maroto J, Font Pous A, Morales Barrera R, Ghanem I, et al. Phase II clinical trial of PM00104 (Zalypsis (R)) in urothelial carcinoma patients progressing after first-line platinum-based regimen. Cancer Chemother Pharmacol. 2014;73(4):857-67 [PubMed]
JCR Factor de Impacto: 2,769
JCR Cuartil: Q2
JCR Decil: D4
JCR Posición: 98/255
JCR Categoría: PHARMACOLOGY & PHARMACY

Cerezo L, De la Torre A, Hervás A, Ruiz A, Liñán O, López M, et al. Oropharyngeal cancer related to Human Papilloma Virus: incidence and prognosis in Madrid, Spain. Clin Transl Oncol. 2014;16(3):301-6 [PubMed]
JCR Factor de Impacto: 2,077
JCR Cuartil: Q3
JCR Decil: D8
JCR Posición: 148/211
JCR Categoría: ONCOLOGY

Ciruelos Gil EM. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev. 2014;40(7):862-71 [PubMed]
JCR Factor de Impacto: 7,588
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 15/211
JCR Categoría: ONCOLOGY

Ciruelos E, Pascual T, Arroyo Vozmediano ML, Blanco M, Manso L, Parrilla L, et al. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. Breast. 2014;23(3):201-8 [PubMed]
JCR Factor de Impacto: 2,381
JCR Cuartil: Q2
JCR Decil: D3
JCR Posición: 21/79
JCR Categoría: OBSTETRICS & GYNECOLOGY

Cortejoso L, García MI, García Alfonso P, Grávalos C, Robles L, González Haba E, et al. Validacion de polimorfismos geneticos asociados a toxicidad al tratamiento quimioterapico en pacientes de cancer colorrectal. Farm Hosp. 2014;38(4):283-90 [PubMed]
JCR Factor de Impacto: – –
JCR Cuartil: – –
JCR Decil: – –
JCR Posición: – –
JCR Categoría: – –

Cusumano PG, Generali D, Ciruelos E, Manso L, Ghanem I, Lifrange E, et al. European inter-institutional impact study of MammaPrint. Breast. 2014;23(4):423-8 [PubMed]
JCR Factor de Impacto: 2,381
JCR Cuartil: Q2
JCR Decil: D3
JCR Posición: 21/79
JCR Categoría:OBSTETRICS & GYNECOLOGY

Escudier B, Grünwald V, Ravaud A, Ou YC, Castellano D, Lin CC, et al. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer. Clin Cancer Res. 2014;20(11):3012-22 [PubMed]
JCR Factor de Impacto: 8,722
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 12/211
JCR Categoría: ONCOLOGY

Faivre S, Castellano D, Strosberg J, González E, Salazar R. Pancreatic NETs: where do we stand now? Cancer Metastasis Rev. 2014;33(1):361-6 [PubMed]
JCR Factor de Impacto: 7,234
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 17/211
JCR Categoría: ONCOLOGY

Gámez Pozo A, Pérez Carrión RM, Manso L, Crespo C, Mendiola C, López Vacas R, et al. The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy. PLoS One. 2014;9(10):e109611 [PubMed]
JCR Factor de Impacto: 3,234
JCR Cuartil: Q1
JCR Decil: D2
JCR Posición: 9/57
JCR Categoría: MULTIDISCIPLINARY SCIENCES

García del Muro X, Gallardo E, García Carbonero I, Laínez N, Méndez MJ, Maroto P, et al. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2014;73(6):1095-107 [PubMed]
JCR Factor de Impacto: 2,769
JCR Cuartil: Q2
JCR Decil: D4
JCR Posición: 98/255
JCR Categoría:PHARMACOLOGY & PHARMACY

García Escobar I, Parrilla L, Ortega LM, Castellanos D, Pallarés MÁM, Cortés-Funés H. Clinical experience with plerixafor as a mobilization regimen for autologous peripheral blood stem cell transplantation in patients with refractory germ cell tumors. Mol Clin Oncol. 2014;2(6):923-6 [PubMed]
JCR Factor de Impacto: – –
JCR Cuartil: – –
JCR Decil: – –
JCR Posición: – –
JCR Categoría: – –

Gómez Martín C, López Ríos F, Aparicio J, Barriuso J, García Carbonero R, Pazo R, et al. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond. Cancer Lett. 2014;351(1):30-40 [PubMed]
JCR Factor de Impacto: 5,621
JCR Cuartil: Q1
JCR Decil: D2
JCR Posición: 24/211
JCR Categoría: ONCOLOGY

Hilario A, Sepúlveda JM, Pérez Núñez A, Salvador E, Millán JM, Hernández Laín A, et al. A prognostic model based on preoperative MRI predicts overall survival in patients with diffuse gliomas. AJNR Am J Neuroradiol. 2014;35(6):1096-102 [PubMed]
JCR Factor de Impacto: 3,589
JCR Cuartil:Q1
JCR Decil: D3
JCR Posición: 43/192
JCR Categoría: CLINICAL NEUROLOGY

Hitt R, Grau JJ, López Pousa A, Berrocal A, García Girón C, Irigoyen A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014;25(1):216-25 [PubMed]
JCR Factor de Impacto: 7,040
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 18/211
JCR Categoría: ONCOLOGY

Llombart Cussac A, Pivot X, Biganzoli L, Cortés Funes H, Pritchard KI, Pierga J-Y, et al. A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial. Breast. 2014;23(5):656-62 [PubMed]
JCR Factor de Impacto: 2,381
JCR Cuartil: Q2
JCR Decil: D3
JCR Posición: 21/79
JCR Categoría: OBSTETRICS & GYNECOLOGY

Martín Algarra S, Fernández Figueras MT, López Martín JA, Santos Briz A, Arance A, Lozano MD, et al. Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2014;16(4):362-73 [PubMed]]
JCR Factor de Impacto: 2,077
JCR Cuartil: Q3
JCR Decil: D8
JCR Posición: 148/211
JCR Categoría: ONCOLOGY

Molina Pinelo S, Gutiérrez G, Pastor MD, Hergueta M, Moreno Bueno G, García Carbonero R, et al. MicroRNA-dependent regulation of transcription in non-small cell lung cancer. PLoS One. 2014;9(3):e90524 [PubMed]
JCR Factor de Impacto: 3,234
JCR Cuartil: Q1
JCR Decil: D2
JCR Posición: 9/57
JCR Categoría: MULTIDISCIPLINARY SCIENCES

Oh WK, McDermott D, Porta C, Levy A, Elaidi R, Scotte F, et al. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review. Int J Oncol. 2014;44(1):5-16 [PubMed]
JCR Factor de Impacto: 3,025
JCR Cuartil: Q2
JCR Decil: D5
JCR Posición: 96/211
JCR Categoría: ONCOLOGY

Prior C, Pérez Gracia JL, García Donas J, Rodríguez Antona C, Guruceaga E, Esteban E, et al. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One. 2014;9(1):e86263 [PubMed]
JCR Factor de Impacto: 3,234
JCR Cuartil: Q1
JCR Decil: D2
JCR Posición: 9/57
JCR Categoría: MULTIDISCIPLINARY SCIENCES

Ramalingam SS, Jänne PA, Mok T, O’Byrne K, Boyer MJ, Von Pawel J, et al. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(12):1369-78 [PubMed]
JCR Factor de Impacto: 24,690
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 3/211
JCR Categoría: ONCOLOGY

Rodríguez Garzotto A, Heine O, Turner M, Rebollo Laserna F, Lorenz A. Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience. J Blood Med. 2014;5:43-8 [PubMed]
JCR Factor de Impacto: – –
JCR Cuartil: – –
JCR Decil: – –
JCR Posición: – –
JCR Categoría: – –

Vermorken JB, Peyrade F, Krauss J, Mesia R, Remenar E, Gauler TC, et al. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). Ann Oncol. 2014;25(3):682-8 [PubMed]
JCR Factor de Impacto: 7,040
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 18/211
JCR Categoría: ONCOLOGY

Von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1269-78 [PubMed]
JCR Factor de Impacto: 24,690
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 3/211
JCR Categoría: ONCOLOGY

Wiechno P, Somer BG, Mellado B, Chłosta PL, Cervera Grau JM, Castellano D, et al. A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer. Eur Urol. 2014;65(3):516-20 [PubMed]
JCR Factor de Impacto: 13,938
JCR Cuartil: Q1
JCR Decil: D1
JCR Posición: 1/78
JCR Categoría: UROLOGY & NEPHROLOGY

Zugazagoitia J, Enguita AB, Nuñez JA, Iglesias L, Ponce S. The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects. J Thorac Dis. 2014;6(Suppl 5):S526-36 [PubMed]
JCR Factor de Impacto: 1,783
JCR Cuartil: Q3
JCR Decil: D8
JCR Posición: 43/58
JCR Categoría: RESPIRATORY SYSTEM

Congresos

Casanovas O, Capdevila J, Barriuso J, Teule A, Castellano DE, Manzano JL, et al. Potential role of mTOR phosphorylation status as a negative predictor to everolimus plus octreotide in NETs. J Clin Oncol. 2014;32(3) [Gastrointestinal Cancers Symposium (San Francisco. 2014)]

Climent Durán MA, Pérez Valderrama B, Fernández Parra E, Mellado B, Domenech M, Fernández Calvo O, et al. Phase II study of weekly cabazitaxel for «unfit» metastatic castration resistant prostate cancer patients progressing after docetaxel treatment: Preliminary toxicity analysis (SOGUG-CABASEM trial). J Clin Oncol. 2014;32(4) [Genitourinary Cancers Symposium (San Francisco. 2014)]

Gávila J, Bermejo B, Manso L, Muñoz E, Antón A, Brunet J, et al. Preliminary results from TRASTYVERE study: A retrospective analysis of heavily pretreated HER2-positive metastatic breast cancer patients treated in Spain with lapatinib plus trastuzumab as compassive therapy. Eur J Cancer. 2014;50:S181 [European Breast Cancer Conference (EBCC) (9. Glasgow, Scotland. 2014]

González Grajera B, Puente J, García Carbonero I, Mohedano N, López Criado MP, Arranz Arija JA, et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract (TCCU) after failure to one cisplatin-based systemic therapy in clinical practice. J Clin Oncol. 2014;32(4) [Genitourinary Cancers Symposium (San Francisco. 2014)]

González Maeso I, Castellano DE, Campos Balea B, Esteban E, Pérez Arnillas Q, Villalobos Leon ML, et al. Meaningful survival after cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): The Spanish experience. J Clin Oncol. 2014;32(4) [Genitourinary Cancers Symposium (San Francisco. 2014)]

Hernando Polo S, González del Alba A, Pérez Valderrama B, Villa Guzmán JC, Climent MA, Laínez N, et al. Vinflunine maintenance therapy versus best supportive care after platinum combination in advanced bladder cancer: A phase II, randomized, open label, study (MAJA study, SOGUG 2011-02)-Interim analysis on safety. J Clin Oncol. 2014;32(4) [Genitourinary Cancers Symposium (San Francisco. 2014)]

Rodríguez Moreno J, Esteban E, Leandro Garcia LJ, Castellano DE, González del Alba A, Climent MA, et al. Retrospective study assessing the association of single nucleotide polymorphisms in VEGFR3 and on-target toxicity in patients with advanced renal-cell carcinoma (RCC) treated with sunitinib. J Clin Oncol. 2014;32(4) [Genitourinary Cancers Symposium (San Francisco. 2014)]

.

2015

Artículos

Aranda E, Aparicio J, Alonso V, García Albéniz X, García Alfonso P, Salazar R, et al. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015. Clin Transl Oncol. 2015;17(12):972-81 [PubMed]

Ares GR, Ciruelos E, Manso L. The need for post-mastectomy radiotherapy in patients with IBC. Nat Rev Clin Oncol. 2015;12(6):370 [PubMed]

Berrocal A, Arance A, Espinosa E, Castaño AG, Cao MG, Larriba JLG, et al. SEOM guidelines for the management of Malignant Melanoma 2015. Clin Transl Oncol. 2015;17(12):1030-5 [PubMed]

Capdevila J, Sevilla I, Alonso V, Antón Aparicio L, Jiménez Fonseca P, Grande E, et al. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer. 2015;15(1):495 [PubMed]

Castellano D, Grande E, Valle J, Capdevila J, Reidy-Lagunes D, O’Connor JM, et al. Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors. Cancer Chemother Pharmacol. 2015;75(6):1099-114 [PubMed]

Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, et al. Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncol. 2015;16(16):1700-10 [PubMed]

De Velasco G, Muñoz C, Sepúlveda JM, Castellano D. Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literature. Can Urol Assoc J. 2015;9(3-4):E243-6 [PubMed]

Diekstra MHM, Liu X, Swen JJ, Boven E, Castellano D, Gelderblom H, et al. Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol. 2015;68(4):621-9 [PubMed]

Diekstra MHM, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RHJ, et al. CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma. Eur Urol. 2015;68(4):621-9 [PubMed]

Domínguez Pinilla N, Baró Fernández M, González Granado LI. Hemophagocytic lymphohistiocytosis secondary to Epstein Barr virus and Leishmania co-infection in a toddler. J Postgrad Med. 2015;61(1):44-5 [PubMed]

Fizazi K, Abrahamsson PA, Ahlgren G, Bellmunt J, Castellano D, Culine S, et al. Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol. 2015;67(5):904-12 [PubMed]

Gámez Pozo A, Berges Soria J, Arevalillo JM, Nanni P, López Vacas R, Navarro H, et al. Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications. Cancer Res. 2015;75(11):2243-53 [PubMed]

García Alfonso P, Chaves M, Muñoz A, Salud A, García González M, Grávalos C, et al. Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. BMC Cancer. 2015;15(1):327 [PubMed]

García Carbonero R, García Figueiras R, Carmona Bayonas A, Sevilla I, Teule A, Quindos M, et al. Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev. 2015;34(4):823-42 [PubMed]

García González X, Cortejoso L, García MI, García Alfonso P, Robles L, Grávalos C, et al. Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer. Oncotarget. 2015;6(8):6422-30 [PubMed]

García Sáenz JA, Bermejo B, Estevez LG, Palomo AG, González-Farré X, Margeli M, et al. SEOM clinical guidelines in early-stage breast cancer 2015. Clin Transl Oncol. 2015;17(12):939-45 [PubMed]

Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer. 2015;113(1):12-9 [PubMed]

Gracia A, Balañá C, Kaskens L, Chiavenna S, Matias-Guiu X, Rubio-Rodríguez D, et al. Economic analysis of EPICUP, an epigenetic test to predict the tissue of origin in cancer of unknown primary site, the USA payors perspective. Value Health. 2015;18(7):A356 [PubMed]

Gracia A, Balañá C, Kaskens L, Chiavenna S, Matias-Guiu X, Rubio-Rodríguez D, et al. Economic analysis of EPICUP, an epigenetic test to predict the tissue of origin in cancer of unknown primary site, from the spanish NHS perspective. Value Health. 2015;18(7):A356-7 [PubMed]

Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J, et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol. 2015;26(9):1987-93 [PubMed]

Guillem V, Climent MA, Cassinello J, Esteban E, Castellano D, González-Larriba JL, et al. Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature. BMC Urol. 2015;15(1):15 [PubMed]

Guillén Ponce C, Serrano R, Sánchez Heras AB, Teulé A, Chirivella I, Martín T, et al. Clinical guideline SEOM: hereditary colorectal cancer. Clin Transl Oncol. 2015;17(12):962-71 [PubMed]

Grande E, Capdevila J, Castellano D, Teule A, Duran I, Fuster J, et al. Pazopanib inpretreated advanced neuroendocrine tumors: a phase ii, open-label trial of the Spanish Task Force Group for Neuroendocrine Tmors (GETNE). Ann Oncol. 2015;26(9):1987-93 [PubMed]

Kamieniak MM, Rico D, Milne RL, Muñoz Repeto I, Ibáñez K, Grillo MA, et al. Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients. Mol Oncol. 2015;9(2):422-36 [PubMed]

Karachaliou N, Mayo de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, et al. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA Oncol. 2015;1(2):149-57 [PubMed]

Llombart Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J, et al. SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015;154(2):351-7 [PubMed]

Llovet P, Sastre J, Sanz Ortega J, Bando I, Ferrer M, García Alfonso P, et al. Prognostic value of BRAF, PI3K, PTEN, EGFR copy number, amphiregulin and epiregulin status in patients with KRAS codon 12 wild-type metastatic colorectal cancer receiving first-line chemotherapy with anti-EGFR therapy. Mol Diagn Ther. 2015;19(6):397-408.

Manso L, Moreno F, Márquez R, Castelo B, Arcediano A, Arroyo M, et al. Use of bevacizumab as a first-line treatment for metastatic breast cancer. Curr Oncol. 2015;22(2):e51-60 [PubMed]

Manso L, Palomo AG, Carrión RP, Cassinello J, Sancho IG, López-Muñiz IC, et al. Factors associated with the selection of first-line bevacizumab plus chemotherapy and clinical response in HER2-negative metastatic breast cancer: ONCOSUR AVALOX Study. Anticancer Res. 2015;35(12):6941-50 [PubMed]

Martín Richard M, Custodio A, García Girón C, Grávalos C, Gómez C, Jiménez Fonseca P, et al. SEOM guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol. 2015;17(12):996-1004 [PubMed]

Martín Richard M, Custodio A, García Girón C, Grávalos C, Gómez C, Jiménez Fonseca P, et al. SEOM guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol. diciembre de 2015;17(12):996-1004

Molina D, Pérez Beteta J, Martínez González A, Sepúlveda JM, Peralta S, Gil Gil MJ, et al. Geometrical measures obtained from pretreatment postcontrast T1 weighted MRIs predict survival benefits from bevacizumab in glioblastoma patients. PLoS ONE. 2016;11(8):e0161484 [PubMed]

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-13 [PubMed]

Olmos VP, Ramos Gallo MJ, Rebollo MA, Ortega DB, Docampo LI, Romera Villegas A, et al. Manejo de la enfermedad tromboembólica venosa en pacientes oncológicos: guías de práctica clínica española. Consenso SEACV-SEOM. Med Clin (Barc). 2015;144(Suppl. 1):3-15 [PubMed]

Paz Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC-H, Wakelee HA, et al. Monotherapy administration of sorafenib in patients with non-small cell lung cancer (MISSION) trial A phase III, multicenter, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens. J Thorac Oncol. 2015;10(12):1745-53.

Paz Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol. 2015;16(3):328-37 [PubMed]

Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, et al. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol.  2015;33(14):1564-73 [PubMed]

Ramón y Cajal T, Chirivella I, Miranda J, Teule A, Izquierdo Á, Balmaña J, et al. Mammographic density and breast cancer in women from high risk families. Breast Cancer Res. 2015;17:93 [PubMed]

Rodon J, Carducci MA, Sepúlveda Sánchez JM, Azaro A, Calvo E, Seoane J, et al. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin Cancer Res. 2015;21(3):553-60 [PubMed]

Rodríguez Garzotto A, Mérida García A, Muñoz Unceta N, Galera López MM, Orellana Miguel MA, Díaz García CV, et al. Risk factors associated with Clostridium difficile infection in adult oncology patients. Support Care Cancer. 2015;23(6):1569-77 [PubMed]

Salazar R, Capdevila J, Laquente B, Manzano JL, Pericay C, Villacampa MM, et al. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer. 2015;15(1):60 [PubMed]

Sastre J, Massuti B, Pulido G, Guillén Ponce C, Benavides M, Manzano JL, et al. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur J Cancer. 2015;51(11):1371-80 [PubMed]

Sepúlveda JM, Belda Iniesta C, Gil Gil M, Pérez Segura P, Berrocal A, Reynés G, et al. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. Clin Transl Oncol. 2015;17(9):743-50 [PubMed]

Sonnenblick A, Francis PA, Azim HA, De Azambuja E, Nordenskjöld B, Gutiérrez J, et al. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. Eur J Cancer. 2015;51(12):1481-9 [PubMed]

Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16(8):990-8 [PubMed]

Sotelo MJ, Sastre J, Maestro ML, Veganzones S, Viéitez JM, Alonso V, et al. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. Ann Oncol. 2015;26(3):535-41 [PubMed]

Villagrasa P, Ciruelos E, Llombart Cussac A, De la Peña L, Vázquez J, Alonso V, et al. P3.03AGATA molecular screening program: implementing precision medicine in patients with advanced breast cancer in Spain. Ann Oncol. 2015;26(suppl 2):ii21 [PubMed]

Zahonero C, Aguilera P, Ramírez Castillejo C, Pajares M, Bolos MV, Cantero D, et al. Preclinical test of dacomitinib, an irreversible EGFR inhibitor, confirms its effectiveness for glioblastoma. Mol Cancer Ther. 2015;14(7):1548-58 [PubMed]

Congresos

Albanell J, Ciruelos E, Colomer R, De la Haba J, Martin M, De Salas Cansado M, et al. Adding Pertuzumab in Neoadjuvant Treatment of Patients with Her2(+) Breast Cancer in Spain: A Cost Offsets Study. Basic Clin Pharmacol Toxicol. 2015;117:42-42.

Antonia SJ, Bendell J, Taylor M, Calvo E, Jaeger D, de Braud F, et al. Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. Ann Oncol. 2015;26:74-5 [Congresso Nazionale Associazione Italiana Oncologia Medica (17. Roma. 2015)].

Calvo E, López Martín J, Bendell J, Eder JP, Taylor M, Ott PA, et al. Nivolumab (nivo) monotherapy or in combination with ipilimumab (ipi) for treatment of recurrent small cell lung cancer (sclc). Asia-Pac J Clin Oncol. 2015;11:118-118.

Motzer RJ, Escudier B, Mcdermott DF, George S, Hammers HJ, Srinivas S, et al. CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC). BJU Int. 2015;116:17-17 [International Kidney Cancer Symposium (14. Miami. 2015)]

Park K, Tan EH, Zhang L, Hirsh V, O’Byrne K, Boyer M, et al. Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7). Ann Oncol. 2015;26:161-2 [Asia Congress of the European Society for Medical Oncology – ESMO (Singapore)]

Thomas M, Zurlo A, Carter R, Aix SP, Knorrenschild JR, Navarro Mendivil A, et al. Immunomodulatory switch maintenance therapy to improve overall survival in small cell lung cancer (SCLC): The randomized IMPULSE study. Ann Oncol. 2015;26:6-6 [European Society for Medical Oncology (Lausanne)]

Wolf J, Hochmair M, Kattan JG, Ang MK, Garon EB, Groen HJM, et al. A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease. Ann Oncol. 2015;26:146 [Asia Congress of the European Society for Medical Oncology – ESMO (Singapore)]

Responder

Introduce tus datos o haz clic en un icono para iniciar sesión:

Logo de WordPress.com

Estás comentando usando tu cuenta de WordPress.com. Cerrar sesión /  Cambiar )

Google photo

Estás comentando usando tu cuenta de Google. Cerrar sesión /  Cambiar )

Imagen de Twitter

Estás comentando usando tu cuenta de Twitter. Cerrar sesión /  Cambiar )

Foto de Facebook

Estás comentando usando tu cuenta de Facebook. Cerrar sesión /  Cambiar )

Conectando a %s